News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

10 years after CAR T-cell therapy: 32–47 percent OS in R/R B-cell NHL
29 Aug 2026
byNatalia Reoutova
A phase II study of patients with heavily pretreated B-cell non-Hodgkin lymphoma (NHL) reports decade-long remissions in approximately one-third of patients with large B-cell lymphomas (LBCL) and in nearly half of patients with follicular lymphoma (FL), following a single infusion of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel.
29 Aug 2026







